US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics–Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics–Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya

June 12, 2018 Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara. EXTON, Pa., June 12, 2018 /PRNewswire/ — Spherix Global Insights’ second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes